ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $838 | – | 75 | -90.4% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 785 | -92.7% | 0.00% | -100.0% |
| Q4 2022 | $517 | -99.9% | 10,732 | -23.8% | 0.00% | -20.0% |
| Q3 2022 | $641,000 | -15.1% | 14,092 | -4.9% | 0.01% | -16.7% |
| Q2 2022 | $755,000 | -35.6% | 14,822 | -4.1% | 0.01% | -33.3% |
| Q1 2022 | $1,172,000 | +33.2% | 15,461 | +3.0% | 0.01% | +50.0% |
| Q4 2021 | $880,000 | -27.1% | 15,016 | -7.9% | 0.01% | -14.3% |
| Q3 2021 | $1,207,000 | +47.4% | 16,311 | -3.2% | 0.01% | +40.0% |
| Q2 2021 | $819,000 | -10.4% | 16,855 | -7.3% | 0.01% | 0.0% |
| Q1 2021 | $914,000 | +1.9% | 18,174 | -3.4% | 0.01% | -16.7% |
| Q4 2020 | $897,000 | +9.1% | 18,818 | +0.4% | 0.01% | 0.0% |
| Q3 2020 | $822,000 | -2.8% | 18,737 | +8.9% | 0.01% | -14.3% |
| Q2 2020 | $846,000 | +0.8% | 17,205 | +9.9% | 0.01% | -12.5% |
| Q1 2020 | $839,000 | +6.2% | 15,657 | +4.1% | 0.01% | +33.3% |
| Q4 2019 | $790,000 | -11.7% | 15,034 | +0.0% | 0.01% | -14.3% |
| Q3 2019 | $895,000 | -26.6% | 15,030 | +0.7% | 0.01% | -30.0% |
| Q2 2019 | $1,220,000 | -17.6% | 14,923 | -4.4% | 0.01% | -16.7% |
| Q1 2019 | $1,481,000 | +25.5% | 15,613 | +1.8% | 0.01% | +20.0% |
| Q4 2018 | $1,180,000 | +0.3% | 15,330 | +0.5% | 0.01% | +11.1% |
| Q3 2018 | $1,177,000 | -38.0% | 15,252 | -0.6% | 0.01% | -30.8% |
| Q2 2018 | $1,898,000 | +45.3% | 15,339 | +1.3% | 0.01% | +44.4% |
| Q1 2018 | $1,306,000 | +23.1% | 15,141 | +3.0% | 0.01% | +28.6% |
| Q4 2017 | $1,061,000 | +41.8% | 14,705 | -2.5% | 0.01% | +40.0% |
| Q3 2017 | $748,000 | +35.8% | 15,087 | +3.5% | 0.01% | +25.0% |
| Q2 2017 | $551,000 | +15.3% | 14,577 | -5.3% | 0.00% | 0.0% |
| Q1 2017 | $478,000 | -5.2% | 15,389 | +3.8% | 0.00% | 0.0% |
| Q4 2016 | $504,000 | +38.8% | 14,831 | +6.2% | 0.00% | +33.3% |
| Q3 2016 | $363,000 | +22.2% | 13,969 | +5.8% | 0.00% | 0.0% |
| Q2 2016 | $297,000 | -30.6% | 13,199 | -2.9% | 0.00% | -25.0% |
| Q1 2016 | $428,000 | +7.8% | 13,594 | +1.2% | 0.00% | 0.0% |
| Q4 2015 | $397,000 | -17.3% | 13,430 | +1.0% | 0.00% | -20.0% |
| Q3 2015 | $480,000 | – | 13,292 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |